Home › Trial NCT03489343
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
- Trial IDNCT03489343
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorSymphogen A/S
- Enrollment24
- Start date2018-05-24
- ConditionsMetastatic Cancer · Solid Tumor · Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.